News coverage about Viking Therapeutics (NASDAQ:VKTX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viking Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.4162501219837 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Viking Therapeutics Inc (VKTX) Expected to Post Earnings of -$0.11 Per Share (americanbankingnews.com)
- Earnings per share (EPS) Evaluation – Viking Therapeutics Inc (NASDAQ: VKTX) (stocksmarketcap.com)
- Bone Fracture – Pipeline Review swot Analysis with leading key players BiologicsMD, Biopharm, Bone Therapeutics SA (journalhealthcare.com)
- Viking Therapeutics, Inc. (VKTX) to touch -6.00% Earnings growth for next year (wallstreetinvestorplace.com)
- Performance Evaluation – Viking Therapeutics Inc (NASDAQ: VKTX) (stockspen.com)
Shares of VKTX traded up $0.02 during trading hours on Friday, hitting $4.41. 427,855 shares of the company were exchanged, compared to its average volume of 799,394. The firm has a market cap of $224.46, a PE ratio of -5.58 and a beta of 2.09. Viking Therapeutics has a one year low of $0.88 and a one year high of $7.36.
Several equities research analysts have recently weighed in on the company. BidaskClub raised Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 7th. Maxim Group reissued a “buy” rating and set a $8.00 price objective on shares of Viking Therapeutics in a research note on Friday, February 2nd. Roth Capital set a $8.00 price objective on Viking Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 8th. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Viking Therapeutics in a research note on Monday, March 26th. Finally, ValuEngine raised Viking Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $9.00.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.